Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

47 results about "Cefpodoxime Proxetil" patented technology

A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.

Solid Pharmaceutical Dosage Form

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid / sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and / or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.
Owner:CIPLA LTD

Novel intermediates for synthesis of cephalosporins and process for preparation of such intermediates

InactiveUS20060135761A1Easily hydrolysableSulfuric acid esters preparationBulk chemical productionCefmenoximeAntibiotic Y
A novel 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate of formula (I) useful in the preparation of cephalosporin antibiotics wherein X is chlorine or bromine; R is hydrogen, C1-4 alkyl group, an easily removable hydroxyl protective group, —CH2COOR5, or —C(CH3)2COOR5, wherein R5 is hydrogen or an easily hydrolysable ester group. The compound of formula (I) is prepared by reacting 4-halo-2-oxyimino-3-oxobutyric acid of formula (IV1), wherein X, R and R5 are as defined above, with N,N-dimethylformiminium chloride chlorosulphate of formula (VII) in an organic solvent at a temperature ranging from −30° C. to −15° C. The cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, cefquinome, ceftazidime, cefteram pivoxil, ceftiofur, ceftizoxime, ceftriaxone and cefuzonam.
Owner:LUPIN LTD

Cefpodoxime proxetil taste-masking granule and preparation method thereof

ActiveCN107625754ASolve the problem of inconvenient medicationImprove stabilityAntibacterial agentsOrganic active ingredientsAdjuvantAdditive ingredient
The invention specifically discloses a cefpodoxime proxetil taste-masking granule and a preparation method thereof, belonging to the field of medicinal preparations. The taste-masking granule is prepared through mixing of a coated cefpodoxime proxetil pellet and a taste-masking particle, wherein the coated cefpodoxime proxetil pellet is of a structure composed of three layers, i.e., a drug-loadedpellet, a separating layer and a smoothing layer from interior to exterior. The main objective of the invention is to overcome the problems that current commercially-available cefpodoxime proxetil products immediately produce unpleasant bitter taste when child patients take the products; the taste of the cefpodoxime proxetil products is bad, which leads to poor medication compliance of child patients; and the cefpodoxime proxetil products have to be dissolved in water before taking, which leads to inconvenience in administration. To improve the medication compliance of children, the inherent bitter taste of cefpodoxime proxetil is totally masked, and components like a sweetener applicable to children are increased, so the bitter taste of the chemical drug is eliminated and fragrant smell is increased; and thus, child patients easily accept the granule and are pleasant to the fragrant smell, so the medication compliance of children is improved. Besides improvement of the medication compliance of children, the granule provided by the invention also overcomes the problem of inconvenience in administration of children by adding special adjuvants which allow children to take the granulethrough direct swallowing without dissolving in water into a prescription.
Owner:COSCI MED TECH CO LTD

Cefpodoxime proxetil soft capsule preparation and its preparing method

The present invention discloses one kind of soft cefpodoxime proxetil capsule and its preparation process. The medicine consists of medicine liquid and capsule shell, the medicine liquid contains cefpodoxime proxetil, matrix and stabilizer, and the capsule shell contains gelatin, glycerin, water, preservative and light screening agent. Compared with available cefpodoxime proxetil preparations, the present invention is even suitable for children and other people incapable of taking care of himself to take and has the advantages of high bioavailability, high stability, accurate content, etc.
Owner:北京瑞伊人科技发展有限公司 +1

Method for prepairng highly purity cefpodoxime proxetil

Highly pure cefpodoxime proxetil can be prepared by a simple process comprising the step of reacting a cefpodoxime salt with 1-iodoethylisopropylcarbonate in an organic solvent in the presence of a crown ether.
Owner:HANMI PHARMA

Cefpodoxime proxetil rapid-release preparation and preparation method thereof

ActiveCN104771368AAvoids tendency to gel with hydrolysisAvoid introducingAntibacterial agentsPowder deliveryFluidized bed dryingAlcohol
The invention provides a cefpodoxime proxetil rapid-release solid preparation and a preparation method thereof. The cefpodoxime proxetil rapid-release solid preparation comprises cefpodoxime proxetil and a surfactant, wherein cefpodoxime proxetil accounts for 2.5-15wt% of the total preparation, and the surfactant accounts for 0.8-15.0wt% of the total preparation. The method for preparing the rapid-release solid preparation adopts wet granulation and specifically comprises the following steps: (1) dissolving cefpodoxime proxetil and the surfactant in absolute ethyl alcohol to obtain a mixture I; (2) after mixing a diluting agent with a disintegrating agent uniformly, slowly adding or spraying the mixture I and carrying out granulation and fluidized bed drying to obtain a mixture II; (3) adding a suspending aid, a flavoring agent and a lubricating agent to the mixture II and carrying out total mixing and subpackaging. The rapid-release solid preparation can be quickly dissolved out when meeting water and can not be gelated. Meanwhile, technology improvement is adopted, thus avoiding the processes of raw material grinding and micronization treatment; and special equipment, such as a dry type granulator, is unnecessary to be used, thus ensuring the product stability while simplifying the production operation.
Owner:SHIJIAZHUANG NO 4 PHARMA

Process for the manufacture of cefpodoxime proxetil

A process for obtaining cefpodoxime proxetil of formula (I), of high purity conforming to pharmacopoeial specifications is disclosed. The process comprises addition of a solution of methanesulfonic acid in water to a solution of impure cefpodoxime proxetil of formula (I) in an organic solvent to form the corresponding cefpodoxime proxetil methanesulfonate of formula (II1), followed by addition of a co-solvent and separation of the aqueous phase containing cefpodoxime proxetil methanesulfonate of formula (II1) having a diastereomeric ratio of (R/R+S) between 0.5 to 0.6 and subsequent neutralization of the methaneulfonate salt (II1) with a base to give cefpodoxime proxetil (I) free of impurities and having a diastereomeric ratio of (R/R+S) between 0.5 to 0.6, or, addition of impure cefpodoxime proxetil of formula (I) to a solution of methanesulfonic acid in water to form the corresponding solution of cefpodoxime proxetil methanesulfonate of formula (II1) in water, followed by sequential addition of a first organic solvent and a co-solvent and separation of the aqueous phase containing cefpodoxime proxetil methanesulfonate of formula (II1) having a diastereomeric ratio of (R/R+S) between 0.5 to 0.6 and subsequent neutralization of the methaneulfonate salt (II1) with a base to give cefpodoxime proxetil (I) free of impurities and having a diastereomeric ratio of (R/R+S) between 0.5 to 0.6.
Owner:LUPIN LTD

Cefpodoxime proxetil compound and preparation method thereof

The invention relates to a cefpodoxime proxetil compound and a preparation method thereof. In the method, the crude product of cefpodoxime proxetil prepared by the prior art is processed by the following steps to obtain a relatively pure cefpodoxime proxetil compound: the crude product of cefpodoxime proxetil dissolves in an organic solvent A; alkali or an organic alkalescent saline solution is added and the mixture is stirred for reaction and hydrolyzed to obtain cefpodoxime salt; the cefpodoxime salt is absorbed with added active carbon and filtered; and then 1-iodoethyl isopropyl carbonic ester is added and reaction is conducted in the presence of an organic solvent B to obtain cefpodoxime proxetil.
Owner:HAINAN MEIDA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products